The design of polyvalent scaffolds for targeted delivery D Vance, J Martin, S Patke, RS Kane Advanced drug delivery reviews 61 (11), 931-939, 2009 | 65 | 2009 |
Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2. 2 S Srinivasan, S Patke, Y Wang, Z Ye, J Litt, SK Srivastava, MM Lopez, ... Journal of Biological Chemistry 288 (4), 2744-2755, 2013 | 59 | 2013 |
Biomineralized anisotropic gold microplate–macrophage interactions reveal frustrated phagocytosis-like phenomenon: a novel paclitaxel drug delivery vehicle AV Singh, M Batuwangala, R Mundra, K Mehta, S Patke, E Falletta, R Patil, ... ACS applied materials & interfaces 6 (16), 14679-14689, 2014 | 56 | 2014 |
Characterization of the oligomerization and aggregation of human serum amyloid A S Patke, S Srinivasan, R Maheshwari, SK Srivastava, JJ Aguilera, ... PloS one 8 (6), e64974, 2013 | 36 | 2013 |
Design of Monodisperse and Well‐Defined Polypeptide‐Based Polyvalent Inhibitors of Anthrax Toxin S Patke, M Boggara, R Maheshwari, SK Srivastava, M Arha, M Douaisi, ... Angewandte Chemie International Edition 53 (31), 8037-8040, 2014 | 22 | 2014 |
Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation S Patke, R Maheshwari, J Litt, S Srinivasan, JJ Aguilera, W Colón, ... Biochemistry 51 (14), 3092-3099, 2012 | 13 | 2012 |
bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies S Patke, J Li, P Wang, D Slaga, J Johnston, S Bhakta, S Panowski, ... MAbs 9 (3), 430-437, 2017 | 12 | 2017 |
A systematic approach to evaluating closed system drug-transfer devices during drug product development S Patke, EN Gaillat, C Calero-Rubio, TB Gooding, H Audat, M Leman, ... Journal of Pharmaceutical Sciences 111 (5), 1325-1334, 2022 | 10 | 2022 |
Succinate Buffer in Biologics Products: Real-world Formulation Considerations, Processing Risks and Mitigation Strategies A Ukidve, KB Rembert, R Vanipenta, P Dorion, P Lafarguette, T McCoy, ... Journal of Pharmaceutical Sciences 112 (1), 138-147, 2023 | 5 | 2023 |
Anti-CD38 antibodies and formulations MC Blondel, C Lemoine, A Virone-Oddos, B Cameron, J Dumas, ... US Patent 11,655,302, 2023 | 1 | 2023 |
Quantification and Stability Impact Assessment of Drop Stresses in Biologic Drug Products M Siavashpouri, CM Bailey-Hytholt, JR Authelin, S Patke PDA Journal of Pharmaceutical Science and Technology 76 (6), 461-473, 2022 | 1 | 2022 |
Anti-complement c1s antibody formulation S Patke, AA Ukidve US Patent App. 18/334,567, 2024 | | 2024 |
Anti-cd38 antibodies and formulations MC Blondel, C Lemoine, A Virone-Oddos, B Cameron, J Dumas, ... US Patent App. 18/300,834, 2023 | | 2023 |
Fgf-21 conjugate formulations T Palm, M Khossravi, S Patke US Patent App. 17/791,341, 2023 | | 2023 |
Anti-tgf-beta antibody formulations and their use KR Bangari, R Latypov, T Mccoy, S Patke US Patent App. 17/843,812, 2023 | | 2023 |
Fgf-21 conjugate formulations T Palm, M Khossravi, S Patke US Patent App. 17/143,938, 2022 | | 2022 |
Fgf-21 formulations T Palm, M Khossravi, S Patke US Patent App. 17/257,530, 2021 | | 2021 |
Excipient choice for protection against metal-catalyzed oxidation: Impact of chelator on stability of biologic drug products M Krause, T Haby, S Patke, M Bolgar, M Huang, L Breckenridge, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018 | | 2018 |
Current Status of Analytical Techniques for Characterization of Protein Stability S Patke, J Stillahn, M Manning Biopharma Asia 7 (1), 18-28, 2018 | | 2018 |
Exploring protein-excipient interactions via on-column screening and complementary methods R Pirnie, M Krause, MO Ogunyankin, F Rinaldi, S Patke, A Narang, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 253, 2017 | | 2017 |